Use of biologic agents in pediatric psoriasis

Journal of Drugs in Dermatology

Volumn 9, Issue 8, 2010, Pages 975-986

  Marji, Jackleen S ^a   Marcus, Rebecca ^a   Moennich, Jessica ^b   Mackay Wiggan, Julian ^a  

^a Department of Medicine   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BIOLOGICAL PRODUCT; BRIAKINUMAB; CALCIPOTRIOL; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; STEROID; TACROLIMUS; TAZAROTENE; USTEKINUMAB; DERMATOLOGICAL AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ABDOMINAL PAIN; ABSCESS; ACUTE AUTOIMMUNE THROMBOCYTOPENIA; ACUTE VIRAL SYNDROME; ANEMIA; BACTEREMIA; BASILAR PNEUMONIA; BIOLOGICAL THERAPY; BLOODY DIARRHEA; BRONCHITIS; BRONCHOPNEUMONIA; CHILDHOOD PSORIASIS; CHRONIC COUGH; CHRONIC IRIDOCYCLITIS; CLOSTRIDIUM DIFFICILE INFECTION; CONVULSION; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; GASTROENTERITIS; GASTROINTESTINAL INFECTION; HAIR LOSS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; JOINT EFFUSION; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTOSIS; LUPUS LIKE SYNDROME; LUPUS VULGARIS; LYMPHOMA; MENTAL DISEASE; MONONUCLEOSIS; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; OVARY CYST; PANCYTOPENIA; PHARYNGITIS; PILONIDAL CYST INFECTION; PNEUMONIA; POPULATION RESEARCH; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; PYELONEPHRITIS; RETROBULBAR OPTIC NEUROPATHY; REVIEW; RISK BENEFIT ANALYSIS; SARCOIDOSIS; SIDE EFFECT; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TOPICAL TREATMENT; TUBERCULOSIS; ULTRAVIOLET B RADIATION; URINARY TRACT INFECTION; UROSEPSIS; UVEITIS; VASCULITIS; VIRAL GASTROENTERITIS; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WOUND INFECTION; ADOLESCENT; AGE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; HOSPITALIZATION; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; AGE FACTORS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 77955900775     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Christophers E. Psoriasis - Epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-320. (Pubitemid 34204344)
2. Hawrot AC, Metry DW, Theos AJ, Levy ML. Etanercept for psoriasis in the pediatric population: Experience in nine patients. Pediatr Dermatol. 2006;23:67-71.
3. Andrews Diseases of the Skin. Philadelphia: Saunders. 2000.
4. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol. 2006;20:370-379.
5. Burden AD. Management of psoriasis in childhood. Clin Exp Dermatol. 1999;24:341-345. (Pubitemid 29491200)
6. Kupper TS. Immunologic targets in psoriasis. N Engl J Med. 2003;349:1987-1990. (Pubitemid 37448920)
7. Farber EM, Nall L. Childhood psoriasis. Cutis. 1999;64:309-314.
8. Gladman DD. Psoriatic arthritis. Dermatol Ther. 2004;17:350-363. (Pubitemid 39390589)
9. Ena P, Madeddu P, Glorioso N, et al. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol. 1985;40:199-205.
10. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-1741. (Pubitemid 44547793)
11. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129:2411-2418.
12. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321-328.
13. Cohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: A population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22:585-589. (Pubitemid 351541054)
14. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829-835. (Pubitemid 44556851)
15. Makredes M, Robinson D Jr., Bala M, Kimball AB. The burden of autoimmune disease: A comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. J Am Acad Dermatol. 2009;61:405-410.
16. Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther. 2008;21:54-59. (Pubitemid 351342175)
17. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology. 2007;215:17-27. (Pubitemid 46976010)
18. Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162:633-636.
19. Vena GA, Vestita M, Cassano N. Can early treatment with biologicals modify the natural history of comorbidities? Dermatol Ther. 2010;23:181-193.
20. Sanfilippo AM, Barrio V, Kulp-Shorten C, Callen JP. Common pediatric and adolescent skin conditions. J Pediatr Adolesc Gynecol. 2003;16:269-283. (Pubitemid 37462096)
21. Parish D, Scheinfeld N. Desonide foam: A review. Drugs Today (Barc). 2008;44:55-62. (Pubitemid 351397413)
22. Brune A, Miller DW, Lin P, et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24:76-80.
23. Shalita AR, Berson DS, Thiboutot DM, et al. Effects of tazarotene 0.1% cream in the treatment of facial acne vulgaris: Pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. Clin Ther. 2004;26:1865-1873. (Pubitemid 40089499)
24. Kaur I, Dogra S, De D, Kanwar AJ. Systemic methotrexate treatment in childhood psoriasis: Further experience in 24 children from India. Pediatr Dermatol. 2008;25:184-188. (Pubitemid 351579599)
25. Andreakos E, Taylor PC, Feldmann M. Monoclonal antibodies in immune and inflammatory diseases. Curr Opin Biotechnol. 2002;13:615-620. (Pubitemid 35448065)
26. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: Results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144:200-207. (Pubitemid 351287002)
27. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: Clinical features and disease mechanisms. Clin Dermatol. 2006;24:438-447. (Pubitemid 44332869)
28. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312. (Pubitemid 40933433)
29. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719-76.
30. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022. (Pubitemid 37448924)
31. Enbrel Prescribing Information. Available at http://www.enbrel.com/ prescribing-information.jspx. Accessed May 18, 2010.
32. Web MD Health News. Available at http://www.webmd.com/skin-problems-and- treatments/psoriasis/news/20080619/fda-panel-oks-enbrel-for-kids-psoriasis. Accessed May 15, 2010.
33. National Psoriasis Foundation. Available at http://www.psoriasis.org/ NetCommunity/Page.aspx?pid=1346. Accessed May 15, 2010.
34. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241-251.
35. Landells I, Paller AS, Pariser D, et al. Efficacy and safety of etanercept in children and adolescents aged ≥8 years with severe plaque psoriasis. Eur J Dermatol. 2010;20:323-328.
36. Kress DW. Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis. J Am Acad Dermatol. 2006;54:S126-S128. (Pubitemid 43243486)
37. Papoutsaki M, Costanzo A, Mazzotta A, et al. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol. 2006;154:181-183. (Pubitemid 43381343)
38. Safa G, Loppin M, Bousser AM, Barbarot S. Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis. J Am Acad Dermatol. 2007;56:S19-S20. (Pubitemid 46074267)
39. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis. 2008;67:1145-1152.
40. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:2794-2804.
41. Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: The Dutch national register. Ann Rheum Dis. 2009;68:635-641.
42. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763-769. (Pubitemid 30151920)
43. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496-1504. (Pubitemid 351705939)
44. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003;48:218-226. (Pubitemid 36091666)
45. Horneff G, Ebert A, Fitter S, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford). 2009;48:916-919.
46. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093-1101. (Pubitemid 36418252)
47. U.S. Food and Drug Administration. TNF Blockers. Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm070725.htm. Accessed May 15, 2010.
48. U.S. Food and Drug Administration. Cancer warnings required for TNF blockers. Available at http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm175803.htm. Accessed May 15, 2010.
49. Diak P, Siegel J, La Grenade L, et al. Malignancy in children and tumor necrosis factor-alpha blockers: Forty-eight cases reported to the food and drug administration. Arthritis Rheum. 2010 Apr 13. [Epub ahead of print].
50. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-1374. (Pubitemid 41443403)
51. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet. 2001;357:1842-1847. (Pubitemid 32539117)
52. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res. 2006;298:7-15. (Pubitemid 43725207)
53. Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol. 2004;21:87-88. (Pubitemid 38248978)
54. Farnsworth NN, George SJ, Hsu S. Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol Online J. 2005;11:11.
55. Pereira TM, Vieira AP, Fernandes JC, et al. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology. 2006;213:350-352. (Pubitemid 44837027)
56. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: An open label study. Ann Rheum Dis. 2003;62:245-247. (Pubitemid 36238089)
57. Pontikaki I GV, Gattinara M, Luriati A, et al. Side effects of anti-TNF-alpha therapy in juvenile idiopathic arthritis. Reumatismo. 2006;58:31-38. (Pubitemid 46785284)
58. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873. (Pubitemid 46454266)
59. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267. (Pubitemid 46175082)
60. Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr. 2005;40:220-222. (Pubitemid 40269746)
61. Remicade (infliximab) [full prescribing information]. Horsham, PA: Centocor, Inc., 2008.
62. Pitarch G, Mahiques L, Perez-Ferriols MA, Fortea JM. Treatment of psoriasis with adalimumab. Clin Exper Dermatol. 2006;32:18-22. (Pubitemid 46006359)
63. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115. (Pubitemid 350298146)
64. Kanakoudi-Tsakalidou F, Tzimouli V, Pratsidou-Gertsi P, et al. The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment. Cytokine. 2008;42:293-297.
65. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810-820.
66. Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol. 2009;104:3042-3049.
67. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149:572-575. (Pubitemid 44468085)
68. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: Current and emerging directed therapies. Ann Rheum Dis. 2005;64 Suppl 2:ii87-90. (Pubitemid 40288531)
69. Pirzada S, Tomi Z, Gulliver W. A review of biologic treatments for psoriasis with emphasis on infliximab. Skin Therapy Lett. 2007;12:1-4.
70. Gade JN. Clinical update on alefacept: Consideration for use in patients with psoriasis. J Manag Care Pharm. 2004;10:S33-S37.
71. Papp KA, Camisa C, Stone SP, et al. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: Review of clinical data. Part II. J Cutan Med Surg. 2005;9:313-323. (Pubitemid 44491081)
72. Dubertret L, Sterry W, Bos JD, et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006;155:170-181. (Pubitemid 43876411)
73. Weinberg JM, Siegfried EC. Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab. Arch Dermatol. 2006;142:555-558. (Pubitemid 43727544)
74. Siegfried E. Long-term follow-up of a child treated with efalizumab for atopic dermatitis. In: V. N. Archives of Dermatology. St. Louis. 2007.
75. Stelara (ustekinumab). Available at http://www.stelarainfo.com/?utm- campaign=Stelara%20Branded&utm-source=google&utm-medium= cpc&utm-content=Branded%20General&utm-term=ustekinumab. Accessed May 18, 2010.
76. Wu JJ. Interleukin-12, interleukin-23, and psoriasis: ABT-874 in clinical trials. J Am Acad Dermatol. 2008;58:1083. (Pubitemid 351657610)